Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.
about
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesCurrent advances in mathematical modeling of anti-cancer drug penetration into tumor tissuesPatient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practiceRadiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approachesGene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patientsToward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma.Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.Pseudo progression identification of glioblastoma with dictionary learningTumor growth rate is an early indicator of antitumor drug activity in phase I clinical trialsKey signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.Mathematical Based Calculation of Drug Penetration Depth in Solid Tumors.A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET.The biology and mathematical modelling of glioma invasion: a review.Mathematical model of perineural tumor spread: a pilot study.Clinical implications of in silico mathematical modeling for glioblastoma: a critical review.MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy.
P2860
Q26775541-BBD81D7F-4069-4BCD-AE46-A7C8071419F4Q26827129-C95EB4FE-0E9F-44CB-A244-095E995347E2Q28083949-D671C5EA-842C-4F8C-B00B-9EAECA825A9AQ30725125-BCB9BF25-CA44-4CF3-8847-87FF80840582Q34117487-E316138D-5468-4458-9F38-48F15EF58283Q35050427-9113321C-64C7-429B-9788-51073F612CCCQ36361484-A0E9EE73-71FF-4760-A227-FE338C488B92Q37391653-711C3DD0-CE55-4D16-B45F-801F85881198Q37626194-C689F47A-C789-4BED-8E4E-75A191796897Q38627721-85411D33-680E-4955-BE9A-07623E419E7AQ40626318-06C1B68D-2D21-4DB4-B6BD-9818D08C0D42Q41650486-6939F14C-C647-4D96-B765-FE548DAFD021Q47124238-119C351D-A5CC-47BB-B503-C6096F61A4AEQ47562348-CEE1A058-2E57-4C1E-B305-38B67F14D0E7Q47627726-EE9FCE17-896C-4961-80AE-A763D9981522Q50671051-AED68F80-9200-4748-87EB-7C029B2CC5B4Q52608753-0181F040-9BA1-4DD9-ABC3-F70C74F0695F
P2860
Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Response classification based ...... ession from pseudoprogression.
@en
Response classification based ...... ession from pseudoprogression.
@nl
type
label
Response classification based ...... ession from pseudoprogression.
@en
Response classification based ...... ession from pseudoprogression.
@nl
prefLabel
Response classification based ...... ession from pseudoprogression.
@en
Response classification based ...... ession from pseudoprogression.
@nl
P2093
P2860
P50
P1433
P1476
Response classification based ...... ession from pseudoprogression.
@en
P2093
Albert Lai
Anne Baldock
Carly A Bridge
Jason K Rockhill
Jordan Lange
Kristin R Swanson
Laura Guyman
Maciej M Mrugala
Sunyoung Ahn
P2860
P304
P356
10.1158/0008-5472.CAN-12-3588
P407
P577
2013-02-11T00:00:00Z